Market Updates | 09th July 2021

The pandemic is accelerating the pace of change right across the professional services sector, amplifying pre-crisis trends as well as triggering entirely new ones. We’ll be keeping tabs on these over the coming months: We’ll be reporting back on what clients are telling us and how we see different segments of the professional services sector perform, as well as highlighting emerging opportunities and challenges. As always, we’ll be taking a fact-based approach. Our market sizing data comes from our unique model of the professional services sector, with more than $1tn of revenues broken down by sector, geography, and capability. Our forecasts are constantly updated to reflect the latest market data we have available from firms and their clients. Client data comes from our rolling programme of quantitative research and interviews.

Pharma & life sciences: From strength to strength

It was the fastest growing sector for professional services during the pandemic, but will it continue to grow once the crisis is over?

Small but perfectly formed would be an apt description of the professional services market in the pharma & life sciences sector (in which we also include medtech). It accounts for around 4% of the total market (just over US $35bn) and is significantly smaller than the healthcare market, which is worth US$54bn.

There are, however, other differences between these markets, interconnected though they inevitably are. As a professional services market, pharma grew in 2020—by around 16% we estimate—whereas the healthcare market shrank in revenue terms. That may seem counter-intuitive to the large consulting, technology, and outsourcing firms that experienced very high levels of demand in the healthcare sector during 2020, but our numbers take into account three significant factors: First, that the lion’s share of new work generated by the crisis went to large firms with the resources to make large-scale change happen quickly; second, faced with an unprecedented crisis, most healthcare organisations cancelled discretionary work to focus on the matter in hand; third, a proportion of the new work generated by the crisis was done either probono, or at a price point significantly below the already low rates typical of this sector.

By contrast, pharma was under immense pressure to innovate rapidly and saw an influx of investment. As a cash-rich sector with vital skills in scarce supply, professional services fee rates rose, and discretionary projects were repurposed to support the efforts around finding, producing, and distributing vaccines. The sector’s exceptional growth was fuelled by technology, which accounts for around a quarter of all expenditure on professional services in this sector. On top of this, more than US$1bn was spent, we estimate, on cybersecurity which has grown 50% against the previous year, and is a testimony not just to new, remote ways of working for many staff, but also concerns about the extent to which drug companies could become targets for cyberattacks. In an industry where intellectual property ownership is pivotal, the amount spent on legal services rose by a third, to around US$3.5bn; a further US$2.5bn went on forensic services. Demand for strategy consulting grew by a fifth, as pharma companies sought to rethink their business models at breakneck speed, but without compromising their future ability to deliver shareholder value.

From an investment point of view, the key question is whether this surge of spending on professional services will continue once the immediate crisis is over. Our modelling suggests that it will, for three reasons. But we also foresee one significant potential risk.

This was one of the fastest growing sectors before the crisis, with typical year-on-year increases in the region of 9-10% at a time when the total professional services market was averaging 7-8%. This was driven by a perfect storm of issues: increasingly onerous regulation; price pressure on products that was creating pressure to keep costs under tight control; the urgent need for new products, coupled with the crippling costs of innovation; and the impact of technology, especially around drug delivery, remote patient monitoring, and telemedicine. Although a very different business, there were important parallels here with the financial services sector, especially in the level of non-discretionary risk and regulation work. The latter accounted for a significant amount of the growth in demand for professional services in the financial services sector in the aftermath of the financial crisis of 2008-09, growth from which the Big Four disproportionately benefitted. Prior to the crisis, we saw evidence of the same happening in the pharma & life sciences sector. If anything, the crisis will amplify this trend going forward: Any industry that becomes more valuable (in a social as well as economic sense) attracts regulatory attention.

A second reason for expecting growth to continue is the level of innovation in the pharma & life sciences sector—and here the situation is very different to that in most financial institutions. As we’ve written about previously in these updates, the professional services sector has a strong record in helping scale innovation, even though it doesn’t excel in idea origination. That will play out well in this sector: With investors looking for opportunities and a likely influx of high-calibre people, inspired by what they’ve witnessed during the pandemic, there’ll be no shortage of client-side innovation. Where clients will need help is in monetising their efforts.

Take both of these points together and we get a third reason to expect recent above-average growth to continue, which is the mix of suppliers at the moment. Unsurprisingly, technology consulting and legal firms have the biggest share of the market—around 19% and 13% respectively. A further 12% is spent on external research support. Risk and regulation makes its presence felt in terms of the 11% of the market that we estimate goes to the Big Four firms. Public relations, critical from a reputational perspective, is over-represented in this market. However, this supplier base reflects only our first driver of growth; these may be, but aren’t necessarily, the firms best placed to help with strategic decisions around which innovations to back, for example. That means that a third source of growth in this market will be the attention and investment made by professional service firms keen to increase their share of a critical market by developing new services that stimulate demand.

And the one significant risk? The market’s size. The reason why the pharma and life sciences sector represents just 4% of the total professional services market is that demand-side consolidation has resulted in a small number of very big companies, which between them account for most expenditure on professional services. The crisis may have created extraordinary opportunities for a new generation of specialists and start-ups, but these don’t buy much in the way of professional support. The ambitious growth plans professional services sectors are already making to grow will need to be tempered by the recognition that they won’t all be able to grow.

All updates

Professional services firms need to start adapting to a multi-shock world 24th June, 2022
Anticipating a slight slowdown in the rate of growth 10th June, 2022
The impact of the professional services market pandemic recedes, but slowly 20th May, 2022
The outlook for professional services by sector in 2022 6th May, 2022
Strategy consulting in an age of crisis 22nd April, 2022
How the Russia-Ukraine war may change client needs 1st April, 2022
Initial thoughts on the impact of the Russia-Ukraine war 18th March, 2022
Tax services: Who stands to benefit from post-crisis growth? 4th March, 2022
Demand for professional services in the healthcare market: Growth through specialisation 18th February, 2022
Productivity improvement consulting and the impact of an inflationary environment 4th February, 2022
The impact of Omicron—and what this tells us about the professional services market in 2022 21st January, 2022
The top three sectors for professional service firms in 2022 26th November, 2021
What price recovery? 11th November, 2021
Supply chain shocks: What impact will they have on demand for consulting? 28th October, 2021
The Central & South America professional services market: In a permanent state of “recovery”? 15th October, 2021
Delivering a more tangible professional service 1st October, 2021
Professional services in the GCC: Post-pandemic resurgence 17th September, 2021
Trying to solve the consulting industry’s value problem 3rd September, 2021
The post-pandemic financial services market 20th August, 2021
Programme management: Why does a potentially valuable service underperform? 6th August, 2021
The consulting market in H1 2021: Outperforming expectations 23rd July, 2021
Pharma and life sciences: From strength to strength 9th July, 2021
Operational improvement services 25th June, 2021
Important lessons from Australia 11th June, 2021
Betting on risk 28th May, 2021
Strong performance in the consulting industry in Q1 2021 14th May, 2021
A fast recovery in the US professional services market 30th April, 2021
How fast will the public sector market for professional services grow in 2021? 16th April, 2021

See the size and shape of your market as you’ve never seen it before

Our model of the global professional services industry is the most powerful of its kind. It’s built from the bottom up and is fully customisable; meaning you not only get to see your market in greater precision and detail, but also in ways you’ve never seen it before.

Explore the model

Plan for what’s coming over the horizon

Our Market Trends Programme is designed to keep you informed about what’s happening in a wide range of geographical and sector-based markets; while our Emerging Trends Programme helps you to stay ahead no matter where, or for whom, you work.

Explore our reports

Make better investment decisions

Whether you’re a private equity firm looking for commercial due diligence or deal origination services, or a professional services firm trying to work out where to invest for growth, we combine world-class market data and peerless industry knowledge to help you distinguish the next big thing from the last big thing.

Find out more about what we do

If you’d like to hear more about how we can help, call us on:

+44 (0)20 3478 1204
+1 (0)800 767 8058
or email us here